AXIM / AXIM Biotechnologies, Inc. - Insider Trading and Ownership Report - SEC Form 3, 4, 5

AXIM Biotechnologies, Inc.
US ˙ OTCPK

Shares Outstanding 355,625,751 shares
Insider Shares88,699,532 shares
Insider Ownership24.94 %
Total Insiders13
Insider Sentiment Score

The Insider Sentiment Score finds the companies being bought by corporate insiders.

It is the result of a sophisticated, multi-factor quantitative model that identifies companies with the highest levels of insider accumulation. The scoring model uses a combination of the net number of insiders buying the prior 90 days, the total shares bought as a percentage of float, and the total shares owned by insiders. The number ranges from 0 to 100, with higher numbers indicating a higher level of accumulation to its peers, and 50 being the average.

Update Frequency: Daily

See Insiders Top Picks, which provides a list of companies with highest insider accumulation.

Officer Sentiment Score

The Officer Sentiment Score finds companies being bought by Corporate Officers.

By definition Corporate Officers are Corporate Insiders, but unlike some of the other Insiders (10% Shareholders and Board Members), Officers work for the company on a daily basis, and they user their own money when trading. (10% Shareholders and Board Members are often fund managers managing other people’s money.) As such, insider trades made by Officers are much more significant and should be treated appropriately.

Like the Insider Sentiment Score, the Officer Sentiment Score is the result of a sophisticated, multi-factor quantitative model that identifies companies with the highest levels of officer accumulation.

Update Frequency: Daily

See Insiders Top Picks, which provides a list of companies with highest insider sentiment.

Key Insider Metrics

This card shows how the company ranks along various insider metrics. The percentile rank shows how this company compares to other companies in the US markets. Higher rankings are indicative of better situations.

For example, it is generally accepted that insider buying is a positive indicator, so companies with more insider buying would rank higher than companies with less insider buying (or even insider selling).

Net Number of Insiders Buying (Rank)

0 ( )

7138 out of 11323

Net Number of Insiders Buying is the total number of insiders buying minus the total number of insiders selling in the last 90 days. The percentile rank is shown here (range from 0 to 100%).

Percent of Float Bought by Insiders (Rank)

0.000 %( )

7059 out of 11244

Percent of Float Bought by Insiders is the total number of shares purchased by insiders minus the total number of shares sold by insiders in the last 90 days, divided by the total float and multiplied by 100.

Insider Trading Chart

AXIM Biotechnologies, Inc. insider trades are shown in the following chart. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on material, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

Insider Roster and Profitability Metrics

This table shows the list known insiders, and is generated automatically from filings disclosed to the SEC. In addition to the names, most recent title, and director, officer, or 10% owner designation, we provide the latest disclosed holdings. Additionally, when possible we provide the historical trade performance for the insider. The historical trade performance is a weighted average of the performance of actual open-market purchase transactions made by the insider. For more information on how this is calculated, watch this YouTube webinar.

See our leaderboard of most profitable insider traders.

Insider Avg Profit (%) Shares
Owned
Split
Adjusted
George Anastassov CEO/Secretary, Director, 10% Owner - [D] [O] [10%] 500,000 500,000
Lekhram Changoer Director, 10% Owner - [D] [10%] 500,000 500,000
Robert L Cunningham Director - [D] 0 0
Glycodots, LLC 10% Owner - [10%] 19,800,000 19,800,000
Insider Avg Profit (%) Shares
Owned
Split
Adjusted
John Walter Ii Huemoeller Chief Executive Officer, Director - [D] [O] 6,000,000 6,000,000
Robert Malasek CFO - [O] 50,000 50,000
Medical Marijuana Inc 10% Owner - [10%] 500,000 500,000
Rosemary Samuels PRESIDENT, CEO, CFO, Director, 10% Owner - [D] [O] [10%] 0 0
Insider Avg Profit (%) Shares
Owned
Split
Adjusted
Foundation Sanammad 10% Owner - [10%] 15,943,650 15,943,650
Blake Schroeder Director - [D] 854,012 854,012
Timothy Richard Scott Director - [D] 0 0
Catalina Valencia President and Director, Director, 10% Owner - [D] [O] [10%] 28,608,220 28,608,220
Damme Philip A Van 10% Owner - [10%] 15,943,650 15,943,650

Report errors via our new Insider Auditing Tool

Track Records of Insider Purchases - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in AXIM / AXIM Biotechnologies, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical .

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2024-01-30 Valencia Catalina 1,086,216 1,086,216 78 0.02
2022-08-24 Valencia Catalina 3,861,004 0.0259 3,861,004 0.0259 100,000
2020-03-19 HUEMOELLER JOHN WALTER II 6,000,000 6,000,000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AXIM / AXIM Biotechnologies, Inc. Insider Trades
Track Records of Insider Sales - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AXIM / AXIM Biotechnologies, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical .

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2014-03-21 SAMUELS ROSEMARY 20,000,000 8,000.0000 20,000,000 8,000.0000 160,000,000,000 731 0.53 -159,989,400,000 -99.99

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AXIM / AXIM Biotechnologies, Inc. Insider Trades
Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b5-1 automatic trading plan will have an X in the column marked 10b-5.

File
Date
Trade
Date
Form Insider Ticker Security Title Code 10b5-1 Direct Exercise
Price
Unit
Price
Units
Changed
Value
Changed (1K)
Remaining
Options
Remaining
Shares
2024-10-15 2024-01-30 4 Valencia Catalina AXIM Common Stock P - Purchase D 1,086,216 28,608,220
2022-09-23 2020-03-19 4 HUEMOELLER JOHN WALTER II AXIM Common Stock P - Purchase D 6,000,000 6,000,000
2022-08-31 2022-08-24 4 Valencia Catalina AXIM Common Stock P - Purchase D 0.0259 3,861,004 100 23,661,004
2022-08-31 3 Glycodots, LLC AXIM Common Stock D 19,800,000
2022-08-31 3 Valencia Catalina AXIM Common Stock D 19,800,000
2022-08-26 2022-08-22 4 Schroeder Blake AXIM Common Stock C - Conversion D 0.0290 854,012 25 854,012
2022-02-15 2022-02-10 4 Schroeder Blake AXIM Convertible Note (Convertible into Common Stock) J - Other D 0.08 25,000.0000 25,000 625,000 307,692
2018-04-06 2018-03-21 4 MALASEK ROBERT AXIM Common Stock A - Award D 50,000 50,000
2017-06-23 3 Cunningham Robert L AXIM Common Stock D 0
2017-06-23 3 Cunningham Robert L AXIM Preferred Stock D 0
2017-06-23 3 MALASEK ROBERT AXIM Preferred Stock D 0
2017-06-23 3 MALASEK ROBERT AXIM Common Stock D 0
2017-06-23 3 Schroeder Blake AXIM Preferred Stock D 0
2017-06-23 3 Schroeder Blake AXIM Common Stock D 0
2017-06-23 3 Scott Timothy Richard AXIM Common Stock D 0
2017-06-23 3 Scott Timothy Richard AXIM Preferred Stock D 0
2017-06-23 3 HUEMOELLER JOHN WALTER II AXIM Preferred Stock D 0
2017-06-23 3 HUEMOELLER JOHN WALTER II AXIM Common Stock D 0
2017-02-28 2016-12-02 5/A Medical Marijuana Inc AXIM Common Stock A - Award D 7,200,000 22,669,125
2017-02-28 2016-11-21 5/A Medical Marijuana Inc AXIM Preferred Stock A - Award D 500,000 500,000
2017-02-15 2016-11-21 5 Anastassov George See footnote 2 AXIM Preferred Stock A - Award I 500,000 500,000
2017-02-15 2016-11-21 5 Anastassov George AXIM Common Stock A - Award D 2,000,000 3,002,000
2017-02-15 2016-11-21 5 Anastassov George AXIM Common Stock A - Award D 250,000 3,002,000
2017-02-15 2016-11-21 5 Changoer Lekhram See footnote 2 AXIM Preferred Stock A - Award I 500,000 500,000
2017-02-15 2016-11-21 5 Changoer Lekhram AXIM Common Stock A - Award D 2,000,000 2,265,000
2017-02-15 2016-11-21 5 Changoer Lekhram AXIM Common Stock A - Award D 240,000 2,265,000
2017-02-15 2016-12-02 5 Medical Marijuana Inc AXIM Common Stock A - Award D 7,200,000 22,143,650
2017-02-15 2016-11-21 5 Medical Marijuana Inc AXIM Preferred Stock A - Award D 500,000 500,000
2016-02-05 2016-02-05 4 Anastassov George AXIM Common Stock A - Award I 125,000 15,365,650
2015-12-30 2015-12-18 4 Changoer Lekhram AXIM Common Stock A - Award D 25,000 25,000
2015-12-30 2015-04-23 4 Changoer Lekhram AXIM Preferred Stock A - Award I 1,000,000 1,500,000
2015-12-30 2015-11-09 4 Anastassov George AXIM Common Stock A - Award I 125,000 15,240,650
2015-12-30 2015-07-02 4 Anastassov George AXIM Common Stock A - Award I 500,000 15,240,650
2015-12-30 2015-04-23 4 Anastassov George AXIM Preferred Stock A - Award I 1,000,000 1,500,000
2015-03-03 2015-02-23 4 Anastassov George AXIM Common Stock A - Award I 2,000 14,945,650
2014-04-30 2014-03-21 4 SAMUELS ROSEMARY AXIM PREFERRED STOCK S - Sale D 400.0000 -1,000,000 -400,000 0
2014-04-30 2014-03-21 4 SAMUELS ROSEMARY AXIM COMMON STOCK S - Sale D 8,000.0000 -20,000,000 -160,000,000 0
2014-04-25 3 Changoer Lekhram Held by Sanammad Foundation AXIM Common Stock I 30,387,300
2014-04-25 3 Changoer Lekhram Held by Sanammad Foundation AXIM Preferred Stock I 15,943,650
2014-04-25 3 Changoer Lekhram Held by Sanammad Foundation AXIM Common Stock I 30,387,300
2014-04-25 3 Changoer Lekhram Held by Sanammad Foundation AXIM Preferred Stock I 15,943,650
2014-04-25 3 Van Damme Philip A Held by Sanammad Foundation AXIM Preferred Stock I 15,943,650
2014-04-25 3 Van Damme Philip A Held by Sanammad Foundation AXIM Common Stock I 30,387,300
2014-04-25 3 Van Damme Philip A Held by Sanammad Foundation AXIM Preferred Stock I 15,943,650
2014-04-25 3 Van Damme Philip A Held by Sanammad Foundation AXIM Common Stock I 30,387,300
2014-04-25 3 Anastassov George Held by Sanammad Foundation AXIM Preferred Stock I 15,943,650
2014-04-25 3 Anastassov George Held by Sanammad Foundation AXIM Common Stock I 30,387,300
2014-04-25 3 Anastassov George Held by Sanammad Foundation AXIM Preferred Stock I 15,943,650
2014-04-25 3 Anastassov George Held by Sanammad Foundation AXIM Common Stock I 30,387,300
2014-04-25 3 Sanammad Foundation AXIM Common Stock D 30,387,300
2014-04-25 3 Sanammad Foundation AXIM Common Stock D 30,387,300
2014-04-25 3 Sanammad Foundation AXIM Preferred Stock D 15,943,650
2014-04-25 3 Sanammad Foundation AXIM Preferred Stock D 15,943,650
2014-04-25 3 Medical Marijuana Inc AXIM Preferred Stock D 15,943,650
2014-04-25 3 Medical Marijuana Inc AXIM Preferred Stock D 15,943,650
2014-04-25 3 Medical Marijuana Inc AXIM Common Stock D 30,387,300
2014-04-25 3 Medical Marijuana Inc AXIM Common Stock D 30,387,300
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista